Niktimvo FDA approval brings new hope for chronic graft-versus-host disease patients
The U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for treating chronic graft-versus-host disease (GVHD) in patients who have not responded to at least two previous systemic therapies. This approval marks a significant advancement in the treatment options available for both adult and pediatric patients weighing at least 40 kg […]